features: Bladder Cancer
EV-103 Cohort K: Promising data for first-line combination therapy of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma
EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…
Top 5 picks from ASCO GU 2022
Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!
FDA gives mitomycin gel green light for low-grade upper tract urothelial cancer
April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper…